Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

OBJECTIVE: To assess the safety and efficacy of dual sodium–glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes. RESEARCH DESIGN AND METHODS: We treated 33 patients with sotagliflozin, an oral dual SGLT1 and SGLT2 inhibitor, or plac...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Care
Autori principali: Sands, Arthur T., Zambrowicz, Brian P., Rosenstock, Julio, Lapuerta, Pablo, Bode, Bruce W., Garg, Satish K., Buse, John B., Banks, Phillip, Heptulla, Rubina, Rendell, Marc, Cefalu, William T., Strumph, Paul
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Diabetes Association 2015
Soggetti:
Diabetes Care Symposium
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4831906/
https://ncbi.nlm.nih.gov/pubmed/26049551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc14-2806
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi